These pioneer studies reported that patients whose colon cancer showed both MSI-high and high intraepithelial lymphocytes (assessed as CD3+, CD8+, and GrB+ cells) had a significantly reduced risk of death as compared to patients having only one of the two features. This evidence concerns the gene CD8A and colonic neoplasm.